Acute kidney injury (AKI), due to its increasing incidence, associated morbidityand mortality, and potential for development of chronic kidney disease withacceleration to end-stage renal disease, has become of major interest tonephrologists and critical care physicians. The development of biomarkers todiagnose AKI, quantify risk and predict prognosis is receiving considerableattention. Yet techniques to accurately assess functional changes withinpatients still rely on the use of an insensitive marker (creatinine),creatinine-based estimating equations and unreliable urinary tests. Therefore,it is critical that functional tests be developed and used in combination withbiomarkers, thus allowing improved care in AKI and chronic kidney diseasepatient populations.
展开▼
